Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
483.96
-10.65 (-2.15%)
Nov 14, 2024, 4:00 PM EST - Market closed
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B in the quarter ending September 30, 2024, with 11.61% growth. This brings the company's revenue in the last twelve months to $10.63B, up 10.06% year-over-year. In the year 2023, Vertex Pharmaceuticals had annual revenue of $9.87B with 10.51% growth.
Revenue (ttm)
$10.63B
Revenue Growth
+10.06%
P/S Ratio
11.75
Revenue / Employee
$1,967,741
Employees
5,400
Market Cap
124.63B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | 4.16B | 1.12B | 36.59% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elevance Health | 174.02B |
Pfizer | 59.38B |
Sanofi | 54.03B |
Bristol-Myers Squibb Company | 47.44B |
Medtronic | 32.58B |
Amgen | 32.53B |
Gilead Sciences | 28.30B |
Danaher | 23.74B |
VRTX News
- 9 days ago - Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It - Seeking Alpha
- 10 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength - Reuters
- 10 days ago - Vertex Reports Third Quarter 2024 Financial Results - Business Wire
- 16 days ago - Vertex to Participate in Upcoming November Investor Conferences - Business Wire
- 20 days ago - Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress - Business Wire
- 25 days ago - Vertex Pharmaceuticals: A Long-Term Growth Monster - Seeking Alpha
- 27 days ago - Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting - Business Wire